Undisclosed CIN-targeting program(s)

About Tailor Bio

Tailor Bio is an early-stage biotech venture targeting a fundamental and widespread driver of cancer: chromosomal instability (CIN). The company is leveraging a proprietary platform to discover and develop small molecules that exploit the unique dependencies of CIN-high tumors, aiming for a novel class of targeted therapies. As a private, pre-clinical company founded in 2021, it is positioned at the cutting edge of oncology research, seeking to address cancers with high unmet need that are often resistant to current treatments. Its success hinges on validating its platform and translating its discoveries into clinical candidates.

Therapeutic Areas